Generation Z (1997–2012). Everything on demand, including healthcare
MHE April 2024
Millennials (1981–1996), burdened by health problems and costly
On specialty drugs, the Prime acquisition and vertical integration
Gen X (1965–1980), still traditional — and stuck in the middle.
The Boomers (1946–1964): Active but aging
Ten biosimilars to Humira are now on the market, but AbbVie’s Skyrizi and Rinvoq are soaking up revenues as Humira’s sales fall off.
The imperative to upgrade healthcare technology infrastructure is clear, but the returns from such investment are anything but.
New federal rules set time requirements for some insurers.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025
2
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
3
Jaypirca shows promise as a frontline treatment for CLL/SLL patients | ASH 2025
4
Positive results for Casgevy but with one patient death from myeloablative busulfan conditioning | ASH 2025
5
